Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses: 2016-2022

Historic Change in Accured Expenses for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2022 value amounting to $973,000.

  • Dianthus Therapeutics' Change in Accured Expenses fell 169.82% to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$2.6 million, marking a year-over-year decrease of 709.15%. This contributed to the annual value of $973,000 for FY2022, which is 535.95% up from last year.
  • Dianthus Therapeutics' Change in Accured Expenses amounted to $973,000 in FY2022, which was up 535.95% from $153,000 recorded in FY2021.
  • In the past 5 years, Dianthus Therapeutics' Change in Accured Expenses registered a high of $5.1 million during FY2019, and its lowest value of -$3.6 million during FY2020.
  • In the last 3 years, Dianthus Therapeutics' Change in Accured Expenses had a median value of $153,000 in 2021 and averaged -$835,667.
  • Per our database at Business Quant, Dianthus Therapeutics' Change in Accured Expenses crashed by 171.39% in 2020 and then skyrocketed by 535.95% in 2022.
  • Dianthus Therapeutics' Change in Accured Expenses (Yearly) stood at $2.2 million in 2018, then spiked by 127.29% to $5.1 million in 2019, then crashed by 171.39% to -$3.6 million in 2020, then surged by 104.21% to $153,000 in 2021, then surged by 535.95% to $973,000 in 2022.